secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001753926-25-000488
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139
--------------------------------------------------------------------------------

- NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.
- Data show smooth, non-fluctuating in vivo release and continuous semaglutide exposure, supporting potential for once or twice-yearly dosing.
- Vivani's proprietary NanoPortal technology demonstrated versatility beyond exenatide implant NPM-115, with in vitro stability over one year.
- First-in-human study LIBERATE-1 for NPM-115 remains on track for top-line data by mid-2025, providing critical information for NPM-139.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000488/0001753926-25-000488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000488/vani-20250326.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer